Hated healthcare names offer defensive value
The guest argued that select large-cap healthcare and pharmaceutical companies are deeply mispriced due to temporary patent cliffs and political overhangs, offering strong cash flows and high dividend yields.
The argument
While the market is highly concerned about the late-2020s Keytruda patent expiration for Merck and post-COVID declines for Pfizer, these companies possess robust pipelines, strong balance sheets, and massive free cash flows to reinvest.
The thesis, stress-tested
✓ What validates it
- ✓Successful patent extensions or formulation updates for key drugs like Keytruda
- ✓Deleveraging progress and positive synergy data from recent pharmaceutical acquisitions
▸ Risks discussed
- ▸Government drug price negotiations and regulatory intervention
- ▸Clinical trial failures or pipeline underperformance
- ▸Integration risks from large, debt-funded acquisitions
Hear it yourself
"It it was also a big sugar heist on Pfizer specifically going out of COVID. And Yeah. I don't think people realized how little people wanted the vaccines, you know, post the pandemic."
00:00 / 00:14
AFFILIATE LINK · ZORTIX MAY EARN A COMMISSION · NEVER A RECOMMENDATION TO TRADE